BioPortfolio Limited La Merie

Competitor Analysis Biogenerics and Therapeutic Proteins
The consolidation process in the biogenerics industry has commenced after first approvals of biogeneric human growth hormone products in the US and the EU and first filings of biogeneric erythropoietin and insulin in the EU. Smaller biogeneric companies have been taken over by generic players from India and Eastern Europe . Large generic and hospital specialist companies have entered the field by acquisition and licensing deals. Apart from biogenerics, the US$ 42 bln market of the major therapeutic proteins (EPO, insulin, coagulation factors, interferons, G-CSF, hGH, enzyme replacement and FSH) is being challenged by competitor projects arising from various technologies. Oral small molecules or oral delivery of packaged or engineered proteins can bypass conventional next generation solutions such as pegylation, fusion proteins or non-invasive drug delivery technologies.

R&D Pipeline News
R&D Pipeline News is a premier information source about research and development (R&D) projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D. R&D Pipeline News covers all relevant treatment modalities, incl. drugs, medical devices, biomaterials, combination products, cell therapy and drug delivery products.